Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Ott

Showing results (471-480 of 504) with videos related to

Pageof 51
Sort By:
Journal of Medicinal Chemistry|April 3, 2009
Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonistsHanna Pettersson, Anne Bülow, Fredrik Ek, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.
International Journal of Environmental Research and Public Health|January 26, 2016
Measuring Indoor Air Quality and Engaging California Indian Stakeholders at the Win-River Resort and Casino: Collaborative Smoke-Free Policy DevelopmentNeil E Klepeis, Narinder Dhaliwal, Gary Hayward, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of MigraineSarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Sleep Medicine|November 29, 2022
Frequency and evolution of sleep-wake disturbances after ischemic stroke: A 2-year prospective study of 437 patientsSimone B Duss, Stefan A Bauer-Gambelli, Corrado Bernasconi, et al.
Health Physics|December 13, 2005
Radioactive materials in biosolids: dose modelingA B Wolbarst, W A Chiu, C Yu, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Respiration; International Review of Thoracic Diseases|December 25, 2022
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung StudyAlexandra Lenoir, Andreas Christe, Lukas Ebner, et al.
Pageof 51

Showing results (471-480 of 504) with videos related to

Sort By:
Pageof 51
Journal of Medicinal Chemistry|April 3, 2009
Synthesis and evaluation of dibenzothiazepines: a novel class of selective cannabinoid-1 receptor inverse agonistsHanna Pettersson, Anne Bülow, Fredrik Ek, et al.
ACS Medicinal Chemistry Letters|June 6, 2014
Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activityGregory R Ott, Rabindranath Tripathy, Mangeng Cheng, et al.
International Journal of Environmental Research and Public Health|January 26, 2016
Measuring Indoor Air Quality and Engaging California Indian Stakeholders at the Win-River Resort and Casino: Collaborative Smoke-Free Policy DevelopmentNeil E Klepeis, Narinder Dhaliwal, Gary Hayward, et al.
Journal of Medicinal Chemistry|June 20, 2020
Structure-Based Drug Discovery of <i>N</i>-((<i>R</i>)-3-(7-Methyl-1<i>H</i>-indazol-5-yl)-1-oxo-1-(((<i>S</i>)-1-oxo-3-(piperidin-4-yl)-1-(4-(pyridin-4-yl)piperazin-1-yl)propan-2-yl)amino)propan-2-yl)-2'-oxo-1',2'-dihydrospiro[piperidine-4,4'-pyrido[2,3-<i>d</i>][1,3]oxazine]-1-carboxamide (HTL22562): A Calcitonin Gene-Related Peptide Receptor Antagonist for Acute Treatment of MigraineSarah J Bucknell, Mark A Ator, Alastair J H Brown, et al.
The European Respiratory Journal|January 9, 2021
Pulmonary function and radiological features 4 months after COVID-19: first results from the national prospective observational Swiss COVID-19 lung studySabina A Guler, Lukas Ebner, Catherine Aubry-Beigelman, et al.
Sleep Medicine|November 29, 2022
Frequency and evolution of sleep-wake disturbances after ischemic stroke: A 2-year prospective study of 437 patientsSimone B Duss, Stefan A Bauer-Gambelli, Corrado Bernasconi, et al.
Health Physics|December 13, 2005
Radioactive materials in biosolids: dose modelingA B Wolbarst, W A Chiu, C Yu, et al.
Bioorganic & Medicinal Chemistry Letters|February 7, 2015
Piperidine-3,4-diol and piperidine-3-ol derivatives of pyrrolo[2,1-f][1,2,4]triazine as inhibitors of anaplastic lymphoma kinaseEugen F Mesaros, Thelma S Angeles, Mark S Albom, et al.
Bioorganic & Medicinal Chemistry Letters|November 16, 2010
Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse modelsEugen F Mesaros, Jason P Burke, Jonathan D Parrish, et al.
Respiration; International Review of Thoracic Diseases|December 25, 2022
Pulmonary Recovery 12 Months after Non-Severe and Severe COVID-19: The Prospective Swiss COVID-19 Lung StudyAlexandra Lenoir, Andreas Christe, Lukas Ebner, et al.
Pageof 51